![otezla](https://pharmaphorum.com/wp-content/uploads/2016/12/otezla.png)
Amgen builds Otezla's psoriasis label as rival BMS looms lar...
Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib, w